Loading
A feasibility study of the Galleri blood test in people with BRCA gene changes who face a high risk of ovarian cancer.
OC-LEAD (NCT07764744) is a non-randomised interventional study sponsored by Weill Medical College of Cornell University with M.D. Anderson Cancer Center. Its primary outcomes are the feasibility of Galleri testing in a surgical BRCA1/2 cohort and of annual testing in a cohort with serous tubal intraepithelial carcinoma.
The registry record, read on 29 October 2026, gives its status as not yet recruiting, with an estimated 70 participants, a planned start in October 2026 and primary completion expected in October 2039.
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/